Little-known startup, backed by Foresite and Samsara, swings $60M China I&I deal
A new, still-in-stealth biotech is paying eight figures to acquire the rights to an experimental I&I drug out of China.
Vignette Bio — a company backed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
